T cell homing to tumors detected by 3D-coordinated positron emission tomography and magnetic resonance imaging

Journal of Immunotherapy

Volumn 30, Issue 1, 2007, Pages 29-39

  Agger, Ralf ^a   Petersen, Mikkel S ^a   Petersen, Charlotte C ^a   Hansen, Søren B ^b   Stødkilde Jørgensen, Hans ^c   Skands, Ulrik ^d   Blankenstein, Thomas ^e   Andersen, Tom E ^a   Hulgaard, Egil F ^d   Jørgensen, Jan T ^d   Marqversen, Jørgen ^c   Gundersen, Hans J G ^a   Hokland, Marianne E ^a  

^a AARHUS UNIVERSITY   (Denmark)

^b Department of Nuclear Medicine   (Germany)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

^d T Cellic A/S   (Denmark)

^e MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

Author keywords

Adoptive cell transfer; MRI; PET; T cell tracking

Indexed keywords

AMINO ACID; IODINE 124; OVALBUMIN; SERYLISOLEUCYLISOLEUCYLASPARAGINYLPHENYLALANYLGLUTAMYLLYSYLLEUCINE; UNCLASSIFIED DRUG;

AMINO ACID TRANSPORT; ANIMAL CELL; ARTICLE; CD8+ T LYMPHOCYTE; CELL LABELING; CELL TRANSFER; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; MALE; MICROSCOPY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RADIOACTIVITY; SENSITIVITY ANALYSIS; T LYMPHOCYTE;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; EGG PROTEINS; FEMALE; IMMUNOTHERAPY, ADOPTIVE; IODINE RADIOISOTOPES; MAGNETIC RESONANCE IMAGING; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; OVALBUMIN; POSITRON-EMISSION TOMOGRAPHY; RECEPTORS, LYMPHOCYTE HOMING;

EID: 33846002377     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cji.0000211326.38149.7e     Document Type: Article

References (32)

1. Peggs KS, Verfuerth S, Pizzey A, et al. Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines. Lancet. 2003;362:1375-1377.
2. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol. 2004;22:329-360.
3. Rosenberg SA, Dudley ME. Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes. Proc Natl Acad Sci USA. 2004;101(Suppl 2):14639-14645.
4. Dudley ME, Rosenberg SA. Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer. 2003;3:666-675.
5. Matsui K, Wang Z, McCarthy TJ, et al. Quantitation and visualization of tumor-specific T cells in the secondary lymphoid organs during and after tumor elimination by PET. Nucl Med Biol. 2004;31:1021-1031.
6. Dubey P, Su H, Adonai N, et al. Quantitative imaging of the T cell antitumor response by positron-emission tomography. Proc Natl Acad Sci USA. 2003;100:1232-1237.
7. Gross S, Piwnica-Worms D. Spying on cancer: molecular imaging in vivo with genetically encoded reporters. Cancer Cell. 2005;7:5-15.
8. Hogquist KA, Jameson SC, Heath WR, et al. T cell receptor antagonist peptides induce positive selection. Cell. 1994;76:17-27.
9. Fidler IJ. Biological behavior of malignant melanoma cells correlated to their survival in vivo. Cancer Res. 1975;35:218-224.
10. Brown DM, Fisher TL, Wei C, et al. Tumours can act as adjuvants for humoral immunity. Immunology. 2001;102:486-497.
11. Guenther I, Wyer L, Knust EJ, et al. Radiosynthesis and quality assurance of 5-[124I]Iodo-2′-deoxyuridine for functional PET imaging of cell proliferation. Nucl Med Biol. 1998;25:359-365.
12. Gundersen HJG, Hansen SB, Gjedde A, et al. A methodology for quantitating and visualising cell homing/accumulation by combined positron emission tomography and magnetic resonance imaging. In: Amini AA, Manduca A, eds. Medical Imaging 2004: Physiology, Function, and Structure from Medical Images. Proceedings of SPIE. Bellingham, WA: SPIE; 2004;5369:361-370.
13. Challis JH. A procedure for determining rigid body transformation parameters. J Biomech. 1995;28:733-737.
14. Rousset OG, Ma Y, Evans AC. Correction for partial volume effects in PET: principle and validation. J Nucl Med. 1998;39:904-911.
15. Petersen CC, Petersen MS, Agger R, et al. Accumulation in tumor tissue of adoptively transferred T cells: a comparison between intravenous and intraperitoneal injection. J Immunother. 2006;29:241-249.
16. Prusoff WH. Synthesis and biological activities of iododeoxyuridine, an analog of thymidine. Biochim Biophys Acta. 1959;32:295-296.
17. Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002;298:850-854.
18. Yee C, Thompson JA, Byrd D, et al. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci USA. 2002;99:16168-16173.
19. Pockaj BA, Sherry RM, Wei JP, et al. Localization of 111indium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy. Augmentation with cyclophosphamide and correlation with response. Cancer. 1994;73:1731-1737.
20. Mukai S, Kjaergaard J, Shu S, et al. Infiltration of tumors by systemically transferred tumor-reactive T lymphocytes is required for antitumor efficacy. Cancer Res. 1999;59:5245-5249.
21. Hanson HL, Donermeyer DL, Ikeda H, et al. Eradication of established tumors by CD8+ T cell adoptive immunotherapy. Immunity. 2000;13:265-276.
22. Kircher MF, Allport JR, Graves EE, et al. In vivo high resolution three-dimensional imaging of antigen-specific cytotoxic T-lymphocyte trafficking to tumors. Cancer Res. 2003;63:6838-6846.
23. Meidenbauer N, Marienhagen J, Laumer M, et al. Survival and tumor localization of adoptively transferred Melan-A-specific T cells in melanoma patients. J Immunol. 2003;170:2161-2169.
24. Palmer DC, Balasubramaniam S, Hanada K, et al. Vaccine-stimulated, adoptively transferred CD8+ T cells traffic indiscriminately and ubiquitously while mediating specific tumor destruction. J Immunol. 2004;173:7209-7216.
25. Koehne G, Doubrovin M, Doubrovina E, et al. Serial in vivo imaging of the targeted migration of human HSV-TK-transduced antigen-specific lymphocytes. Nat Biotechnol. 2003;21:405-413.
26. Kuyama J, McCormack A, George AJ, et al. Indium-111 labelled lymphocytes: isotope distribution and cell division. Eur J Nucl Med. 1997;24:488-496.
27. Ponomarev V, Doubrovin M, Serganova I, et al. A novel triple-modality reporter gene for whole-body fluorescent, bioluminescent, and nuclear noninvasive imaging. Eur J Nucl Med Mol Imaging. 2004;31:740-751.
28. Commerford SL. Biological stability of 5-iodo-2′-deoxyuridine labelled with iodine-125 after its incorporation into the deoxyribonucleic acid of the mouse. Nature. 1965;206:949-950.
29. Ahrens ET, Flores R, Xu H, et al. In vivo imaging platform for tracking immunotherapeutic cells. Nat Biotechnol. 2005;23:983-987.
30. Bollard CM, Aguilar L, Straathof KC, et al. Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease. J Exp Med. 2004;200:1623-1633.
31. Barth RF. A critical assessment of boron neutron capture therapy: an overview. J Neurooncol. 2003;62:1-5.
32. Mortensen MW, Sorensen PG, Bjorkdahl O, et al. Preparation and characterization of Boron carbide nanoparticles for use as a novel agent in T cell-guided boron neutron capture therapy. Appl Radiat Isot. 2005.